Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
STAT4
REST API REST API
Homo sapiens
STAT4 is differentially expressed in 254 experiments: 111 organism parts: cerebellum, spleen, ... (109 more);, 181 disease states: normal, control, ... (179 more);, 109 cell types 217 cell lines 26 compound treatments and 65 other conditions.
Orthologs stat4 (Danio rerio)   Stat4 (Mus musculus)   stat4 (Xenopus laevis)   A4IFU4_BOVIN (Bos taurus)   (Compare orthologs)
InterPro Term SH2, STAT_TF_alpha, STAT_TF_prot_interaction, STAT_TF_DNA-bd
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, cytokine-mediated signaling pathway, cytoplasm, cell proliferation, transcription, DNA-dependent, signal transducer activity, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, nucleus, JAK-STAT cascade, signal transduction, calcium ion binding, sequence-specific DNA binding transcription factor activity, protein phosphorylation
UniProt Accession Q53S87, Q53RU2, C9JFG0, Q14765, C9JM11, D3DPI9, B7SIX5, E9PBE2, E9PG69
Gene-Disease Assocation RHEUMATOID ARTHRITIS; RA, SYSTEMIC LUPUS ERYTHEMATOSUS; SLE, SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 11; SLEB11
Search EB-eye ENSG00000138378
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, E-MTAB-62, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-18005, E-GEOD-19397, E-GEOD-2450, ... (27 experiments)

Factor Value U/D Experiments
A549
1
2
E-GEOD-3202, E-GEOD-6013
DU145
2
E-GEOD-17482, E-GEOD-20089
HL-60
2
E-GEOD-24147, E-MTAB-37
UACC893
1
E-MTAB-37
HMCB
1
E-MTAB-37
NCIH441
1
E-MTAB-37
211 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, ... (45 experiments)

Factor Value U/D Experiments
endothelial cell
3
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
CD8+ T cell
1
3
E-AFMX-5, E-GEOD-6740, E-TABM-145, E-GEOD-19069
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
103 more value(s).


Disease state

studied in E-MEXP-1121, E-GEOD-16363, E-MTAB-680, E-MTAB-62, E-GEOD-5418, ... (51 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-62, E-MEXP-231, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-37
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
glioblastoma
1
2
E-GEOD-6014, E-GEOD-4290, E-MTAB-62
control
1
2
E-GEOD-20295, E-GEOD-8121, E-GEOD-21912
Down syndrome, acute megakaryoblastic leukaemia
1
E-MTAB-62
175 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (19 experiments)

Factor Value U/D Experiments
none
3
6
E-TABM-868, E-MEXP-1958, E-GEOD-7400, E-MEXP-2285, E-GEOD-412, ... (9 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
placebo
1
E-MEXP-1327
anti-CD3 + anti-CD28
1
E-GEOD-7307
20 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-TABM-147

Environmental stress
studied in E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-TABM-321, E-TABM-868, E-TABM-601, E-MEXP-1838, E-GEOD-17347 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-12773, E-GEOD-20540, E-GEOD-20504, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-MEXP-2069, ... (34 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, E-GEOD-7114 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-23984 ... (5 experiments)

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-22152, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-15799 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271

Processing time: 0.281 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM